" /> PhenX - human papillomavirus vaccine use protocol 100802:-:Pt: Patient:-:PhenX - CISMeF





Preferred Label : PhenX - human papillomavirus vaccine use protocol 100802:-:Pt: Patient:-:PhenX;

LOINC status : ACTIVE;

LOINC long common name : PhenX - human papillomavirus vaccine use protocol 100802;

LOINC short name : PhenX - HPV vaccine use protocol;

LOINC description : The interviewer asks the individual whether s/he ever received a human papillomavirus (HPV) vaccination. If the response is yes, the interviewer asks about number of shots received. If the participant answers yes to question 1, the interviewer should complete the rest of the protocol. If the participant answers no, then the protocol is deemed complete. The PhenX Working Group notes that GARDASIL is also known internationally as Silgard. European Medicines Agency. (2009, September 25). Silgard European Public Assessment Report. Waknine, Y. (2006, October 2). International approvals: Singulair and Gardasil/Silgard. Medscape Today. Note: GARDASIL by Merck & Co. is approved by the U.S. Food and Drug Administration (FDA) for use in females ages 9-26 and males ages 9-26. Note: CERVARIX is manufactured by GlaxoSmithKline Biologicals and approved by the FDA for use in females ages 10-25.;

Détails


Vous pouvez consulter :


Nous contacter.
30/07/2025


[Accueil] [Haut de page]

© CHU de Rouen. Toute utilisation partielle ou totale de ce document doit mentionner la source.